As of Nov 19, 2026, 2 of 2 active firms rate HSDT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HSDT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -98% YoY
Next period, 1 analysts expect Helius Medical Technologies Inc Class A to earn $-0.02 a share (range $-0.02 – $-0.02), versus $-1.30 a year earlier. Full-year consensus is $-0.74, growing to $-0.09 the year after.
REVENUE · NEXT QUARTER
$2.9M
Range $2.8M – $2.9M · 1 analysts · -21% YoY
Revenue is expected to reach $2.9M (range $2.8M – $2.9M), -21.3% year-over-year. Full-year consensus is $12.3M, rising to $11.4M next year.
Top analysts covering Helius Medical Technologies Inc Class A
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HSDT.
#1
Matthew Galinko
Maxim Group · Rank #565
Buy
$4.00+145.4% to target
Overall win rate
23%
+ Follow
#2
FS
Fedor Shabalin
B. Riley Securities
Buy
$4.00+145.4% to target
Coverage
—
+ Follow
HSDT stock forecast FAQ
What is HSDT's average 12-month price target?+
The 2 active firms with a live target average $4.00 for Helius Medical Technologies Inc Class A over the next 12 months, ranging from a $4.00 high to a $4.00 low, as of Nov 19, 2026.
Is HSDT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover HSDT?+
2 active firms have a recognized rating on Helius Medical Technologies Inc Class A as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HSDT?+
Among analysts who currently cover HSDT, Matthew Galinko of Maxim Group has the strongest overall Quantellect track record (Rank #565). Their current call is Buy with a $4.00 target.
What is Helius Medical Technologies Inc Class A's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $-0.74, rising to $-0.09 the following year.
How much revenue is Helius Medical Technologies Inc Class A expected to report next quarter?+
Consensus revenue is $2.9M (range $2.8M – $2.9M). Full-year revenue is projected at $12.3M, growing to $11.4M next year.
Have analysts been upgrading or downgrading HSDT lately?+
As of Nov 19, 2026, 2 of 2 active firms rate HSDT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HSDT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.